Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 901–1,000 of 1,000
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 7
Wiederhold, N. P., & Herrera, L. A. (2012) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8016 · Cited by 7
Deep-seated Candida infections in the intensive care unit
Brusselaers, N., Blot, S. I., & Vogelaers, D. (2011) · Ghent University Academic Bibliography (Ghent University) · Cited by 9
Efficacy and safety of caspofungin in children: systematic review and meta-analysis
Rosanova, M. T., Bes, D., Aguilar, P. S., Cuellar‐Pompa, L., Sberna, N., & Lede, R. (2016) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2016.305 · Cited by 6
Tascini, C., Sozio, E., Paolo, A. D., Tintori, G., Leonildi, A., Bertolino, G., Carmassi, F., Tagliaferri, E., Menichetti, F., & Barchiesi, F. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1289308 · Cited by 6
Prevention and Management of Complications
Kanodia, A., Verma, H., Jain, A., Kalsotra, G., Kumari, S., Agrawal, S. K., Gautam, H., Kaushal, D., Gugliani, A., & Lodha, J. (2021) · Springer eBooks · doi:10.1007/978-981-33-6284-0_8 · Cited by 9
[Treatment with caspofungin of Candida tropicalis endocarditis resistant to fluconazol].
Castillo, M. D., Wainsztein, N., Klein, F., Manganello, S., & Orellana, N. (2004) · PubMed · Cited by 6
Approaches to Management of Invasive Fungal Infections in Patients with Hematologic Malignancies
Forrest, G. N., & Walsh, T. J. (2004) · Supportive Cancer Therapy · doi:10.3816/sct.2004.n.019 · Cited by 6
Antifungal susceptibility against yeasts isolated from pediatric oncology patients
Kersun, L. S., Reilly, A. F., Ingram, M. E., Nicholaou, M., & McGowan, K. L. (2008) · Medical Mycology · doi:10.1080/13693780701874523 · Cited by 7
Patterson, T. F. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0018-4 · Cited by 9
Optimising antifungal therapy for individual patients
Hope, W. W., & Denning, D. W. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00569.x · Cited by 7
Les antifongiques dans le traitement des infections invasives
Carle, S. (2003) · Pharmactuel · Cited by 13
Emerging opportunistic fungal infections: where are we heading?
Idemyor, V. (2003) · PubMed · Cited by 11
Deshpande, K. M. (2003) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01214-0 · Cited by 6
Antibiotic management of sepsis: current concepts
Bugano, D. D. G., Camargo, L. F. A., Bastos, J. F., & Silva, E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2817 · Cited by 7
Wu, L., & Tapia-Herrera, G. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0008-8 · Cited by 6
Principles of Antifungal Therapy
Pappas, P. G. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0135 · Cited by 6
Echinocandins: A promising new antifungal group
Randhawa, G. K., & Sharma, G. (2004) · Indian Journal of Pharmacology · Cited by 8
Theodore, D., Henneman, A. D., Loo, A. S., Shields, R. K., Eschenauer, G. A., Sobieszczyk, M. E., & Kubin, C. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae175 · Cited by 5
Kurland, S., Furebring, M., Löwdin, E., Olaison, L., & Sjölin, J. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf312 · Cited by 6
Hayatshahi, A., Javadi, M., Torkamandi, H., Hadjibabaie, M., Hanafi, S., Gholami, K., Alimoghaddam, K., Iravani, M., & Ghavamzadeh, A. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 5
Kurland, S., Löwdin, E., Furebring, M., Shams, A., Chryssanthou, E., Lagerbäck, P., Tängdén, T., Breuer, O., & Sjölin, J. (2021) · Mycoses · doi:10.1111/myc.13386 · Cited by 5
Lehmann, D. M., Cohen, N., Lin, I., Alexander, S., Kathuria, R., Kerpelev, M., Taur, Y., & Seo, S. K. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac555 · Cited by 5
Tutaj, K., Szlązak, R., Starzyk, J., Waśko, P., Grudziński, W., Gruszecki, W. I., & Luchowski, R. (2015) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2015.07.011 · Cited by 7
Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico
Zaragoza, R., & Pemán, J. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.009 · Cited by 10
Paradoxical Interpretations of Noninferiority Studies: Violating the Excluded Middle
DiNubile, M. J., Sklar, P. A., Lupinacci, R. J., & Eron, J. J. (2012) · Future Virology · doi:10.2217/fvl.12.101 · Cited by 5
Self-citationDoes the current treatment of invasive fungal infection need to be reviewed?
Martín‐Peña, A., Aguilar‐Guisado, M., & Cisneros, J. M. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.02.008 · Cited by 7
Pemán, J., & Almirante, B. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13128779 · Cited by 10
Mycoses bronchopulmonaires (aspects immunoallergiques exclus)
Germaud, P., Boutoille, D., & Gay‐Andrieu, F. (2010) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(10)19078-1 · Cited by 6
Pharmacoeconomics of antifungal therapy: current considerations
Ashley, E. D. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399604.68268.79 · Cited by 6
Puesta al día en la candidiasis invasora en el paciente crítico no neutropénico
Zaragoza, R., Ramírez, P., Borges-Sa, M., & Pemán, J. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.03.001 · Cited by 8
Outcome of Candida parapsilosis complex infections treated with caspofungin in children
Devrim, İ., İşgüder, R., Ağın, H., Bayram, N., Ceylan, G., Ayhan, F. Y., Sandal, Ö. S., Sarı, F., Aksay, A. K., & Duzgol, M. U. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.042 · Cited by 6
Neofytos, D., Steinbach, W. J., Hanson, K. E., Carpenter, P. A., Papanicolaou, G. A., & Slavin, M. A. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.011 · Cited by 5
Zinter, M. S., Levy, E. R., & Gertz, S. J. (2015) · Journal of Pediatric Intensive Care · doi:10.3233/pic-14093 · Cited by 5
Garnacho‐Montero, J., & Gil, C. L. (2005) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(05)73677-1 · Cited by 8
Shoham, S., Groll, A. H., & Walsh, T. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00149-0 · Cited by 6
Saullo, J. H., & Alexander, B. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00038-5 · Cited by 5
Karthaus, M., & Hentrich, M. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01978.x · Cited by 5
Issues in the design and interpretation of antifungal drug trials in the critically ill
Ostrosky-Zeichner, L. L. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328331fc5f · Cited by 6
Treatment of invasive fungal infections
Bellmann, R., & Weiler, S. (2011) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-011-0290-3 · Cited by 5
Infectious Disease Update: New Anti-Microbials
Yang, A., & Kerdel, F. A. (2006) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2006.04.006 · Cited by 8
Traitement des candidémies chez un patient porteur d’un cathéter vasculaire
Gallien, S., Sordet, F., & Angoulvant, A. (2007) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2006.10.006 · Cited by 12
Rol de voriconazol y caspofungina en terapia antifúngica
Teresa Bidart, H. (2004) · Revista chilena de infectología · doi:10.4067/s0716-10182004021100002 · Cited by 5
Bretagne, S. (2005) · Antibiotiques · doi:10.1016/s1294-5501(05)80161-x · Cited by 7
Tolérance de la caspofongine chez les patients de réanimation : étude prospective
Constantin, J.-M., Roszyk, L., Guerin, R., Bannier, F., Chartier, C., Perbet, S., Futier, E., Cayot-Constantin, S., Sapin, V., & Bazin, J.-É. (2008) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2008.06.013 · Cited by 5
Diagnostic et prise en charge des infections sur cathéter en réanimation
Timsit, J., Wolff, M., Mourvillier, B., Schortgen, F., & Regnier, B. (2003) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(03)00237-3 · Cited by 9
Li, M., Hsueh, P., Lu, C., Chou, H., Lee, P., Chang, L., & Huang, L. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.01.005 · Cited by 5
Wang, L., Wang, Y., Gao, X., gang, J. Z., Liu, J., & Dong, S. (2013) · Indian Journal of Pathology and Microbiology · doi:10.4103/0377-4929.120377 · Cited by 5
Nosocomial Candida infections: epidemiology of candidaemia
Gallé, F., Catania, M. R., & Liguori, G. (2006) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2006.47.3.78 · Cited by 5
Aixia, W., Yingyuan, Z., He, L.-X., Zhi-xiang, S., Liao, W., Mingzhe, H., Li, R., De-rong, L., Shaoxi, W., Hahn‐Ast, C., et al. (2006) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2006.370 · Cited by 5
Amphotericin B use in children: conventional and lipid-based formulations
Kuyucu, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.5 · Cited by 7
Épidémiologie des candidoses invasives en France
Charles, P., Large, A., Quenot, J., & Dalle, F. (2016) · Réanimation · doi:10.1007/s13546-016-1183-6 · Cited by 5
Actualización sobre el tratamiento de las infecciones fúngicas graves
Guerra, M. (2008) · Revista española de quimioterapia. Suplemento · Cited by 7
Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts
Michallet, M., Sobh, M., Deray, G., Gangneux, J., Pigneux, A., Larrey, D. G., Ribaud, P., Mira, J. P., Nivoix, Y., Yakoub‐Agha, I., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.010 · Cited by 5
Krcmery, V. (2005) · Medical Principles and Practice · doi:10.1159/000084627 · Cited by 11
Cortés, J. A., & N, J. A. R. (2011) · Revista chilena de infectología · doi:10.4067/s0716-10182011000700004 · Cited by 17
Fungal infections and their treatment in the intensive care unit
Sarosi, G. A. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.ccx.0000244128.92612.50 · Cited by 5
Antifungal Agents and Antifungal Susceptibility Testing
Revankar, S. G., Graybill, J. R., & Patterson, T. F. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0134 · Cited by 5
Moeremans, K., & Annemans, L. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.14.1931 · Cited by 6
Blyth, C. C., Hale, K. A., Palasanthiran, P., O'Brien, T. A., & Bennett, M. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006343 · Cited by 5
Zhu, T., Tu, J., Sun, S., Zhao, Z., Lu, H., Wen, S., Xu, S., Ge, Y., You, Q., Sheng, C., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.016 · Cited by 4
Clarke, F., Grenfell, A., Chao, S., Richards, H., Korman, T. M., & Rogers, B. A. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae302 · Cited by 4
Pantothenate kinase is an effective target for antifungal therapy
Regan, J., DeJarnette, C. A., Reitler, P., Gihaz, S., Srivastava, A., Ge, W., Tucker, K. M., Peters, T. L., Meibohm, B., Mamoun, C. B., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.007 · Cited by 6
Atighehchian, M., Latifi, G., Bardan, A. S., Ouano, D. P., Zarei‐Ghanavati, S., Abedinifar, Z., & Zarei-Ghanavati, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-22615-w · Cited by 4
Management of invasive fungal infections in the pediatric intensive care unit
Fisher, B. T., Zaoutis, T. E., & Chiotos, K. (2015) · Journal of Pediatric Intensive Care · doi:10.3233/pic-14108 · Cited by 4
Helical peptide–polyamine and –polyether conjugates as synthetic ionophores
Benincasa, M., Francescon, M., Fregonese, M., Gennaro, R., Pengo, P., Rossi, P., Scrimin, P., & Tecilla, P. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.034 · Cited by 4
Invasive Candidiasis in the Neutropenic Cancer Patient
Gamaletsou, M. N., Sipsas, N. V., & Kontoyiannis, D. P. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0044-4 · Cited by 6
Takesue, Y., Oda, S., Fujishima, S., Aikawa, N., & Mikamo, H. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0371-1 · Cited by 4
Innovative Antimykotika zur Therapie invasiver Pilzinfektionen
Glöckner, A. (2011) · Der Internist · doi:10.1007/s00108-011-2873-9 · Cited by 5
Fungal Infections of Bones and Joints
Ruderman, E., & Flaherty, J. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00112-1 · Cited by 4
Bendel, C. M. (2006) · Elsevier eBooks · doi:10.1016/b0-72-160537-0/50035-9 · Cited by 4
Efficacy of Amphotericin B in Corneal Preservation Media After Extended Frozen Storage
Huh, D., Tran, K. D., Straiko, M. M. W., McCarthy, M. W., Loo, A. S., Walsh, T. J., & Sáles, C. S. (2020) · Cornea · doi:10.1097/ico.0000000000002381 · Cited by 4
The Disinfectant Effect of Modified Hydrothermal Nanotitania Extract on Candida albicans
Noor, N. F. M., Yusoff, M. E., Rahman, M. A. A., Alam, M. K., & Harun, A. M. (2021) · BioMed Research International · doi:10.1155/2021/6617645 · Cited by 4
Groll, A. H., Simon, A., & Lehrnbecher, T. (2005) · Springer eBooks · doi:10.1007/3-540-29036-2_79 · Cited by 4
Nivoix, Y., Fohrer, C., Fornecker, L., & Herbrecht, R. (2006) · Medical Mycology · doi:10.1080/13693780600931986 · Cited by 4
Infection in the Patient with Cancer
Freifeld, A. G., & Kaul, D. R. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00036-9 · Cited by 4
Komorowski, A. S., Bai, A. D., Cvetkovic, A., Mourad, O., Lo, C. K. L., Li, X. X., Mokashi, V., Findlater, A. R., Duncan, D. B., Fuller, C., et al. (2022) · PubMed · doi:10.1128/aac.01627-21 · Cited by 1
Anttila, V., Salonen, J. H., Ylipalosaari, P., Koivula, I., Riikonen, P. V., & NIKOSKELAINEN, J. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01709.x · Cited by 4
Infectious Complications of Cancer Therapy
Safdar, N., Crnich, C. J., & Maki, D. G. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_76 · Cited by 5
Progress in antifungal therapy: Echinocandins versus azoles
Nailor, M. D., & Sobel, J. D. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.06.001 · Cited by 6
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
Pfaller, M. A., Diekema, D. J., Castanheira, M., & Jones, R. N. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0053-y · Cited by 4
Anidulafungin: advantage for the newcomer?
Rüping, M. J. G. T., Vehreschild, J. J., Farowski, F., & Cornely, O. A. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.207 · Cited by 4
Candida bloodstream infection: A clinical microbiology laboratory perspective
Pongrácz, J., & Kristóf, K. (2014) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.61.2014.3.11 · Cited by 4
Garbino, J., Markham, L. N., Matulionytė, R., Rives, V., & Lew, D. (2005) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500372887 · Cited by 4
Mele, G., Musci, M., Musto, C., D’Amato, L., Traficante, A., & Renzo, N. D. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704987 · Cited by 4
Antimicrobial prophylaxis in solid-organ transplantation
Bassetti, M., Righi, E., & Bassetti, D. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14789072.2.5.761 · Cited by 4
Infectious Diseases in Pediatric Cancer
Koh, A. Y., & Pizzo, P. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00027-3 · Cited by 4
Mucocutaneous and Deeply Invasive Candidiasis
Shoham, S., Nucci, M., & Walsh, T. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00088-4 · Cited by 4
Simple HPLC Method for the Determination of Caspofungin in Human Plasma
Y, M. S. M. S. (2015) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.1000137 · Cited by 4
Infections After Transplantation
Holt, C., & Winston, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00078-6 · Cited by 5
Groll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 6
Colombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(12)70336-7 · Cited by 6
Self-citationHarrison, T. S., & Brouwer, A. E. (2005) · Medicine · doi:10.1383/medc.33.5.116.64952 · Cited by 4
Steinbach, W. J., & Dvorak, C. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00295-6 · Cited by 5
Gea‐Banacloche, J., & Wade, J. C. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_21 · Cited by 4
Darouiche, R. O. (2004) · Clinical Infectious Diseases · doi:10.1086/423391 · Cited by 4
Antibiotika bei Sepsis und Multiorganversagen
Müller, E. E. (2007) · Steinkopff eBooks · doi:10.1007/978-3-7985-1729-5_5 · Cited by 4
Jl, M., & Solomon, P. J. (2003) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00886-4 · Cited by 4
Behlau, I. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50345-3 · Cited by 4
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.